<SEC-DOCUMENT>0001193125-13-416117.txt : 20131029
<SEC-HEADER>0001193125-13-416117.hdr.sgml : 20131029
<ACCEPTANCE-DATETIME>20131029170059
ACCESSION NUMBER:		0001193125-13-416117
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20131029
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20131029
DATE AS OF CHANGE:		20131029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		131177010

	BUSINESS ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		11080 CIRCLEPOINT ROAD
		STREET 2:		SUITE 140
		CITY:			WESTMINSTER
		STATE:			CO
		ZIP:			80020

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d619144d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant
to Section&nbsp;13 or 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the&nbsp;Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): October&nbsp;29, 2013 (October 29, 2013) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ARCA biopharma, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-22873</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>36-3855489</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>11080 CirclePoint Road, Suite 140, Westminster, CO 80020 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(720) 940-2200 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
Name or Former Address, if Changed Since Last Report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8 &#151; Other Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01. Other Events. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;29, 2013, ARCA biopharma, Inc. announced that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for the GENETIC-AF clinical trial of Gencaro (bucindolol hydrochloride), a
pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation, and has established the Data Safety Monitoring Board for GENETIC-AF. The press release is furnished as Exhibit 99.1 hereto, the contents of which are
incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01. Financial Statements and Exhibits. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d)
Exhibits. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces IND Submission to U.S. FDA for Gencaro for the Treatment of Atrial Fibrillation&#148; dated October 29, 2013.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: October&nbsp;29, 2013 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ARCA biopharma, Inc.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">(Registrant)</P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christopher D. Ozeroff</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Christopher D. Ozeroff</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">SVP and General Counsel</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:28.45pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit<BR>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release titled &#147;ARCA biopharma Announces IND Submission to U.S. FDA for Gencaro for the Treatment of Atrial Fibrillation&#148; dated October 29, 2013.</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d619144dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g619144img002.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARCA BIOPHARMA ANNOUNCES IND SUBMISSION TO US FDA FOR GENCARO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE TREATMENT OF ATRIAL FIBRILLATION </B></P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GENETIC-AF Trial Data Safety
Monitoring Board Established </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Westminster, CO, October&nbsp;29, 2013</I> &#150; ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company
developing genetically-targeted therapies for cardiovascular diseases, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the GENETIC-AF clinical trial of Gencaro
(bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation (AF). ARCA has identified common genetic variations that it believes predict individual patient response to Gencaro,
giving it the potential to be the first genetically-targeted AF prevention treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Data Safety Monitoring Board (DSMB) for the GENETIC-AF trial
has been established. It is comprised of experts in the fields of cardiology, electrophysiology and statistical analysis, particularly in clinical development. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>GENETIC-AF Clinical Trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GENETIC-AF is planned as a
Phase 2B/3, multi-center, randomized, double-blind clinical trial comparing Gencaro to Toprol XL for prevention of AF in patients with heart failure and reduced left ventricular ejection fraction (HFREF). ARCA plans to enroll only patients with the
genetic variant of the beta-1 cardiac receptor which the Company believes responds most favorably to Gencaro. GENETIC-AF has an adaptive design, under which the Company plans to initiate it as a Phase 2B study in approximately 200 patients and then,
depending on the results of an interim analysis by the trial Data Safety Monitoring Board (DSMB), expand the trial to a Phase 3 study by enrolling an estimated additional 420 patients. The Company anticipates that patient enrollment in GENETIC-AF
will begin in the first quarter of 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About ARCA biopharma </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases. The Company&#146;s lead product candidate, Gencaro<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for atrial fibrillation. ARCA has identified common genetic variations
that it believes predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted atrial fibrillation prevention treatment. ARCA has a collaboration with Medtronic, Inc. for support of the GENETIC-AF
trial. For more information please visit <U>www.arcabiopharma.com</U>. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Safe Harbor Statement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements regarding, potential timing for patient enrollment in the GENETIC-AF trial, the sufficiency of the Company&#146;s capital to support its operations, the potential for genetic
variations to predict individual patient response to Gencaro, Gencaro&#146;s potential to treat atrial fibrillation, future treatment options for patients with atrial fibrillation, the role of AF burden in diagnosis and treatment of atrial
fibrillation and the potential for Gencaro to be the first genetically-targeted atrial fibrillation prevention treatment. Such statements are based on management&#146;s current expectations and involve risks and uncertainties. Actual results and
performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: the Company&#146;s financial resources and whether
they will be sufficient to meet the Company&#146;s business objectives and operational requirements; results of earlier clinical trials may not be confirmed in future trials, the protection and market exclusivity provided by the Company&#146;s
intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA&#146;s
filings with the SEC, including without limitation the Company&#146;s annual report on Form 10-K for the year ended December&nbsp;31, 2012, and subsequent filings. The Company disclaims any intent or obligation to update these forward-looking
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Derek Cole </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">720.940.2163 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>derek.cole@arcabiopharma.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g619144img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g619144img002.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`3`#4`P$1``(1`0,1`?_$`+\````&`P$!````````
M```````"!P@)"@$%!@,$`0`#`0`"`P$!`````````````0(#!P@$!@D%"A``
M``4#`P($`@8&!0@+`0```0(#!`41!@<`$@@A$S%!%`DB%5%A<:$R%H'A0F(C
M%\%2,Q@*DK,D=#6U=C>1T7*B0U,T9(65)AD1``$#`@0$!`,$"`4%``````$`
M$0(#!"$Q$@5!808'47$B$X&1,K$4%0CPH7*RTC-#"<%28I*3@B-3)%3_V@`,
M`P$``A$#$0`_`+VE_92L[&<4K,WA*(QC0E2HD$X'=/%0"O:9MPH=<_7K3PKK
MTKKCN#TIV[VB>\]474*%M%@!G.1.0C'Q7Z>U;/N.\W(M["F9^)X1\TSQ_P"X
M18R;HR<59%QRC.I@3=G<HL#J4,(`/I56BIR`:G3XM=,MS_N"=!6-W.WMMHOJ
M]",B!,5(Q$@.+&!9<CT.TVXU:7N5+JG"39&)/Z]2\D_<$MQ00*&-K@`XG(F4
MHRS6HF4.!`"OH.GCK\P?W$^BI58TH;#?F4B`&K0S.7]->73[.WM2F:GWZB`/
M]!_B65?<"MU$YR&QM<&Y,YDSTEFH[3E,)1`?]!^D-.?]Q'HJG6E0GL-^*D20
M7K0S&?\`32I]GKZI1C5^^T6E/3]!^?U++/W"K(.[(C)6-<4<U$Q04=$>(O1(
M`C0P@W3:)G.)?HJ&OT+#^X+T-=W-.C7V:^HT9D`S-6)T@\2-`P43[/;H(5)4
MKJE.4"<-)#M_U)X-B97LW),2$S:$FE)M0(0RZ(&!-ZS.?P2>-1J=`XCTH/C3
M7<GH;N3T=W%V_P"_]*7D+E@\H#ZHGP(7&N[;'N.R5O:W&F8>!X'R2@E<%-3I
M01I0!'Q\_H\M>]@@D1/U$+\=\'.7#FC]S]W[_P!6KTI:E@RVTHFVUIY5^OKY
M>6D8LC4M:>>BRO\`Y25XV/+>G%W\L!8@/?2`)2BZ%#^T!N43!4U*`(@&I5<^
M"V0*B(`(EH(^5?#[M5I4ZEGN?N_?^K3THU(`H80`2IF$!\*B!1^CJ41`0&NH
M5+.\_P#Y0_Y1/OZZ2$-QP_\`#'ZZ&*(_]%0KIH6.[XU*(4&G4?O\/`=4`ZG4
MAW/W?O\`U:>E&I#N_N_?^K2THU+Q6>MV[95VY52;MD`,99=90J:*1"!4RBBA
MJ%*4OG]&HQ5)/"9GQ.HZ]$GD:R3O-_;]*6Y(T5]]=NWM@MOW;NE*:'3TR\"N
M_:R+9^@5TP51?-C"(%7:K)JIC3QVF*-#4T)+Z"K;R@8"B`#X5&@_I"G35B+A
M29,C=S]W[_U:>E&I?([DFK%%PY>JD:M&B"CET[<'!)LW;HD,HJJJL:A2$23*
M)C"/0"A74%@4P7664DUD6S=ZQ53=LG:*;EJ\0.51LX05*4Z2J*I:E.15,P&*
M(=!*-=./J02R^KN?N_?^K5:4M2SW`IX=?HK_`$TTM*-2@@Y-WW+9!S#<R#M=
M=6-MY\:%AV&XPMFR;=),YU@1#X>XX%7J(U'IKX/?FJ[E;GUMW.W"SO#.G8;7
M7]B%,2.F6F()GI!9\?#!=JNWVS':-JIU:6@&O3U/)AF^&/DN9M?'3UZV3D6R
M)E6HB4ZYR_$=JH`U#ODZB1,1\!Z`.N(NFNWVZ]16]'=).;/7C&,2=(?.1X?%
M>?N6^`2J4:Q$:T,!D!+R\?@G)Q6'$'+^UI%!K5A,O(X!`"@)472;U))9NKT$
M-RI2"H'[HZ[7;7^7ZPA=;15A3$[>[N:0U"+Q!U1)&K)^2])J=4U*,:D929HG
M!^2]I3#B)92['2S,"Q\(_E#JB!*`NH#U5%NV1I0.Y\8&#Q^$HZ\WJ+L+M]3J
MO>;B5(0M-OG,F1BT'Q`#Y.>`XJ++JBM.SHPA-YF>3XMY)M5TX[?,$UI`Z1T6
MH"(%5.4`[YAKN303``,J`#XG+4H:ZC]0]N=VV*UJ;E6C+V92,@"","7&?)<B
M;;OLR=%-C*6?FOJX[7O+8[R_:2C19PBRG9=O`3+(BI@:KL7YMAUE$!$2"L@!
M:E&E0$=<E_EG[B[AT/W1V^I85J@VZZJBE5@YTRUX##+Q7YO7&S?C&P5*UU[?
MWB`>+,[#]:GA1$BBB>P34*`*`(^`@<@"%!`*=`'7WKI5J=0B1BTY1!^8!_Q7
M4VM(U)@1^F!9;'7D*%\KURV9M'3QXN1LS9MUG;MPH8"IH-6J9EW"JAAZ%(FB
MF81$>@`&E+)5'-4P('W(;@1]Z%;,EP3C^-P],7,;CXNB9TZ&WB8V:+KQL9=C
M./,IZ-92X)!JS<=TA1,.ZH&UD,^:UR+')71RF*8I#$,!B'(4Y#%&H&(8H&*8
MH^8"`ZV#<%BC:$E%'S0]MS&>;FV4<RPN0\P8ORBYMZ9N4)6S+XF8^(=R<#!'
M%F@_A3.5696BI8],IRH$1&@B/4?'(Q(Q6PD_I56;V\+3RQS"Y91N`,D<A,QQ
MEEQHS;B=6@+VF$)1^A#*/6?HVKE5=<B(.G;4#"<Q3;""/F&DV#JG+E^"LJ7U
M[,&)5[8>%QCG+D78-^H,USP%SIY-F)-()A-,3L59EDX.JFZ:F7*!3E3`IJ&K
MH(PQ4B>."B_X.>Z!R6XT<KE>$_,ZZ'&2+<3O];&"%_S1VJ4[:$V*AD(EZHZ!
M%L5Y:7\(Q1`X'7&I1`_0:L%L4%B=/'@5;>*<AR$4(8#$4*4Z9@\#%.`&((?]
MHHAK5\'*R;%E##[H/NSVWPI398JQ3$M<E<B+C0/Z:"263=P]FI."]MFXN!NT
M4%V\EW:_PMH](2N!,)3&*)#``YF3GDK$0`YSX)M7&7VY^0_,>+BL^>Y;FG)T
MN[N-)&4LS`]M7`_M6`@+:>`5Z5E=98(L69;U150[:`&(LDF8`.;<`B,XYJG`
MS4B$O[2OM]24"K"DX[149O;"V1DHV[,A)S+,PE`I7;9Z:[3_`.E)FZ@)]X;O
M+0`EJ.2@'YS^WKECVZ\@8IY`8&RQERY>/:&1;<2NN(F;UN.0D[$=.9!)$GS0
MOKC,7ML.RJG`AQ2#L`2B@CN*(A51Q.'Q5P:WY%&8@H:7;J`JA*14=((G`Q3E
M,FZ9(*@('+\)JB:M?IUI$N'*RD&*V^J4J$GWVN1TIAOA^^QQ:3]=K>F>'RUI
M(+1KLZ<M%6PR:C)7`_319G*_(T>LD5&@K$H!15'X@H.LY8E:P!$7&:W7L;<G
M?Y_<-(.T9N57DKYP6[)C^?5>O"N7*\3Z<'MJ*$`YS.E$6MO`@@90^X1,GU,(
MUT1SQ2GDZF<`0'P$!^S6BS6="%`C=K-LXS1?I'*)U2GNER([!VG*'9;4V=0)
M_E=-?SS]S[.ENG?;?+*NYMSNM34`W^6GXKMI93N*?3-I4D'B*$6^93RL3VF@
M#ENM;\I'NC'`I7L+(40<N$#T*JBJ)]C-8*>`D$1"M==Y.S_0EF:MI'8KNAHB
M(FM0J,-4,-3DX9/Q7%_46YU)P,IP,JL2T3X)4VE^1",HZMJRXY%=HQDRK*O'
M1NXDTE$MJ2I([9N`Y$3@):FZ5#7+DNX>R[?NT^G.B;2-2%"Y8F;2A3J.Q--G
M#OX+\/\`"+BK1A>W\F$HY'B$IZ\<#]DDVN-BF1H]?C(*+-1!,7C[M'*F5[7;
M1-0YNHAYCKEV[VRWW+;H;3U91B!<S%;5##WJF8A4\1YK\85S9W+VI]3,.039
MLIV>D=5T\N23CV`$)VV<*Q,5=9!),!!))($MZ"8B'XA-01IUUU1[T]#BL:UW
MO]U;TK.((A0@`XCPC@,2%[IT]NER:L=.HXXE,>CF+=IE6QRMT3D3"[8P2"H(
M"<P"J:AC"4=@_HU\^^D]OM]K[L[7;VDO_5EN=$Q'@-17*E[7G<;'7G4^KVRI
MZ&/X$/\`5D?\TGK^B*A_*I?L1_="ZE#*?[9^U;37EJ5&+[KW(I_A/B[,VA9J
MXCE?/<DTP]CIDV5K(FD+J71823Y!JD(NE$FL6NM4Q2[2B/40UG*3K6`XJOK[
MS_!LW'W"W#S*EKPB;$+/L*T</9-?,4#$&0OR)81CB&GWZB(;TU55XAR)U34`
M1`/BJ.I5$N,>"LE>V1GE/D5PJP=?3J6)+7/'VFSM*]EO4=]8+NMQ%)E,BJ(G
M,H'<.)3!OH8:ZJ.:B?CQ3^M:+-</DW_EID;_`(#N_P#W`_U,LE<,U2>]CD@F
M]R.4H`C1A?Q^@5Z%G)H1'[``*C]6HX+09R/Z9J\7(R3*'9.Y25=-XZ,CFZSQ
M_(/EDFK-HU;D,JLNX<KG3112(0HB)CF`H>8ZHRX+,1+JB7<F,;D]P+W:KW-A
MA@\E['<9J!Y/7ZR9KO+:A+9MEZ=5W,N)IND>/*<^\H)I]WO*5':4:#2/UK1L
M7.05U//N3FF!<!Y'RH[[*Q<:V')3R*:QMB3IY$1PF:H"/_N%TP+]/75RP'-9
MQ#R5,CVDL8O.;WN/2^8,K`K=+&SCSF8+G/(B=Z5>8D7SAO8_>%?N%[4=(LD0
M*0W00)2FHY*W#D\5>D#I3;T)3\-`#J'X:=.@`3H`>&M1$!9$DYHVFDN%R5C>
MS<O61/XYR%"M[BLVZ6A6$]#.C*$1>M"K)."D[B1B*I'*N@0P&*)3!3H/72E$
M2"J,C$N%T4!!QMLPL7;T.AZ6)AF2$=&MNXHKZ=DU(":"/=5,90_;(%*F$1T1
M#!D2.HNMH<VP`-N`A2B`G,82@0I:]1.)N@%#1(L$AFJ_-DVTS]RCFMRVO68;
M)2V%,+8OGN..+'3A$'$8O?DPB["7G&:@@9MWHY>24'>D(F`2``CK%B2_!;OI
M#*(SV9LB3_$;W$KLXZ7>N9@PO-U<&(95M**&CT/G5L2KQ2(GMBHI)J+R#6%*
MFD<U1,1;X1H.FI;$Q^2N\I4V]`I\0U+_`%1KU`/.@#K49+(KTTTE!9.20,\S
MWX/904$+F=[@53[HF_@-NFW::H?5KX!=55K6T_,-O\[FC[K[I4TC@^BFNUU+
MW:O2EK&-5B*`P^)3[L9+N))BDHK#VY'LU6JR(2SX$FZR!ETNVF9H1-,ZY5@$
M:A\(!KZ$]L*=SN-A.VE965G"M0E3A5,@)DRBP$<'=RN(-VA<4*NKW)3D).8@
M9@8E-DM.X'F/KLF[<N$AF3R/F72Y%'9%&Z2S9TY4606;J'*":Z:R:I3=!\1Z
MZZG]-]0;CVQZONNF>I-=K<0O9SC.L"(U![A+QD0QPYKWN[L?QW:J%S9&)U18
MQ</$LG.IY.4N=:,A(\XNU5W*)2>FWJIE*0X**"L=(#`0I$R":HT\-=M+#N/<
M]9[A9[+M5;[Q&5>,Y5(.1&(S#C`+T#<-F&VDFX/K`6QRDZ6:M%WK:W[=D6>S
M;\T8B@LN8P`-3ND5"D5*:OC0!'7Z/=NYKPHU:QLK*^IB):4)`SB!_F#/J'%/
MI^%&=8'WI@ODV2CT^:^KRI8U6R*'_P"NC0V$3`ABAWA``*&T-I0'7S%VV[H[
MCWGVJM3HBA*.YT@8C+ZN*YCE3C3Z?N!&9G_VSFIR6/X4/]71_P`T37]!U'^7
M2_8C^Z%U2&4_VS]JV=2UH(T\!'K2@"-*U\M>6<DE5YSCE'+_`"G]S].Z\%8;
M_O#6#P@;&AFD,23")MT;\F`4.]?/I7>4BLA%.UU")D*53^S"O36!Q+K<``>`
M2_\`,BX^>W+#CCD[!]X\!VL4PNF"6]%<*-_&>N[<E6`E=MIQ@VHGWW#=%%0A
M2B8!-W*4&NGCX(:(R.*8A_AX.1;FR<K9-XJ74J,<E=Z#NZK782)_1JLK@@3;
M9Q@DV4$*.W_JP$4Q`#B*8=!TP6*@AP1Q"M[ZU62X?)O_`"TR-_P'=_\`N!_J
M99*X9JAM[66,;GR]SGF;1L[+%QX6GJ7R[;7M:D8QFI9($9J8.#08^37;,A:K
M')0QA,(@!AZ#K/RP*T`8DI?_`'5FW/'B_DN'L'+G(G)>7L`7BDS?P4RW,O9$
M=>4:@X;FN.TKL0MMXK'MWQA-VR$'=O+\7EH8(U'-6;?:]FN,%V<2[$NOB[8\
M+8%JRB2S:Z;=8J@[F6-X1QO33;"Y954A)*7=M'9C%35=5,)!^'H(B-1;XJ)D
MX>"VWNCV[*W-P,Y',(<%!<M["D9)4B)3&4.SCTS+NB%(0!,;<D`]`#3GDBGF
M57B_PU%Q1,?GWD+;;Q9!&8G\46>I%HJG*15T$/<LJN_02*8044.W14[A@`!$
MH!UIJ<D\P>2N.:U62&A"*8Q2A4P@`!YCH);-&9;BLUZ5&H!X]0$.GT]=#H4>
M?N@\EAXQ<0<BW7%*F->MW($QW8C)N8QI%Q<5U@,8BYCT$_XBZ\:#@%J%Z@(!
MJ)G!EK3#EU&]P;E^>O$_CO9>,;5X&$N99P12[;AO)_??RR0NN=N50\NM,/V(
M"N#9R*;T$S$W!39U"NLPZLB)S.(4*WN=17(:P.6%J\N<AX"<<?YN[Y&VIIBP
MCYA28BGT[8JS!%PL@^`P$;R,FQ:G,JB!2`<%1,`:8#X)',-\U=>XRYLA.0V!
M\89AA7+59.^+6C)1^DV4*H5E.':I?.8X^W\*K)^)R&*/4*==:0+A9S#'DEYU
M2A5_\AR3B$S+D`Y1.@J%S.Q`^W:9+^`UJ:OB7IYZ_G;[T7-_M?>3J"_M@8W$
M-UF0#Q!C#)=Q>GK"UOM@M8#`>P'/D2G!8TO=FS,WFYE;USK87T#%4W<4=+)#
MO*X=C4.TT0``,7H.\>G378GL_P!Q;.E0I[WO-45[JC`&C1E+#W!D6Y'AQ7IW
M46SU(ZH6@T@.#+-QR\TYE25M&]6%O)W["Q4](3DD0S9=VV)W8V+.L#;8V-41
M2#N^'U===KKG>^E.MMOV^7<.QL-PW6^O(Q:<(^BG,B`'P=UQS"UW*QJ3K;?4
MG3IPB[9@GBO5O-6M9[.ZF-E1L;!R-OR"RQ3MDR&5D8E!86BJ3D1$OJ`$Y@Z?
M1UUY5'J#I/H?9]ZV_H+;[/;;[;;LQUPB#[D`[@#ADRP]B_W&,+B_,J@J8-DQ
MX%-LR1><:[*O,0ZOHGIDC*/V2*PE,FL;KZEEY'15$:F(%`+T"HZZC]TNY-C?
M;;5WKIJI*UW:H2:U)_JD?JEY'P7O>S;57M:D8U*7HP8MP37;2D74YE6Q#'$Z
MSE6[H<@?#4ZQC+'ZB(?M!KK5VPE=;UW/VFK=%[B>X4Y$@8X'P7(6^48VNP5:
MT2/9-,@D8,3P5@5HGL*@%>H-T@$/`0$$R`(?:%-?T2T`3"`&0C']T+J!*.B)
M/C,_:FM<XN1EM<6.,.6LN7'(),E(JTI:/MQN*I"NY"YY=FM'02#)$3`=8Y))
MRD<^T!HF41'PUY$E,<TTWV;\`O\`#?$B'O.Z$!+D7/LR]RS?"RB@**&<SRBS
MN.3`X!42@Q>%';6@5TH<U4R^`4L1DP.80.!#$&@"4Q0'<0P"10IJ^(&*(A]@
MZHQ<NH!;!4.><,7<'`SW:+@RE`($BV'\TXG-5OHM2`#4;=N==51S%)%*(!Z<
MA4*&3\`UGCEQ"U=B#P(5XO%V0;?RGCFR\C6I(MY>W;QMV*G(N0;*%.BX1?-B
M*'VB434$BVXM!ZU"FK!PYK.0Q7ME$Y4L89(4.(%(2P;P,8QC`4H`%OR`C4QJ
M`&G+)$/J5)KV.U4O_P"DK\HJ$+WF%^&2$YBD!8WSJ9/L0$1_C&V]:!UIJ'P6
MG&1_3-6Y.;/$^SN8W'J]<.W2T1+(2$<XD+/F!3`'5O76V1%2-?-5!$!3%10!
M2/Y;5!'RU4H\5$9`8'(JH+[=O*W('MB<P[FP?G`7L-C2XKI_)658IX!S(6U*
M)+>EAK_CMP%`S!`PGWB4`*L"E:A34<RJ.!TG+Q5XE\VM;(]GO6*RK*?M"[X!
M1NLJ@LFZ82D+,M=IC%43WD42<MU!`/MU1D2&4@:2ZHPY"L;*'LV^XS#9%3CI
M&0QT%Q3,K;4FFV4=,[IQC="YB7#&$4*`)A.1[)5P1%(P[BB4H@.I#\<PKP&/
M`J[KA?-..L_XZMK*.+KCC[FM2Z(UI(M73!PFLHS4<($57CWZ11WM7S%8QDE2
M"'PJ$$.NM(R?`K.42,4J@]`$?HU2A-3YA\K,;\0\(75EK($LR;+QT<Z2M2WU
M')`DKGN15(R<7%QS3^U<'5<#41H``4H]=9RE\UI&+YY+B?;HR!ES+7$G'.6,
MU2))&\LD_,[R1`C<K-*.MZ4<5A8LB0&,!4V:"0]1I7=IQ+XHFPP"C-Y,W7'\
MV?=7X_\`$^+E6\GC/B^66RUD-NW,7MN,B1S-)TV@GZQ1,#I)LBV0'92@'./U
MZ@XE6`T2K""12%("12$(FF`)D33H!")%`"ID*```%*5.@`'E36HQ"Q.:A]]\
M+!*F9>"EZ2K"/"1G,32;3(<04``5T3-R_*78H5_8*Q?F$Q?,"U\M1(-DM($%
MP4P#_#I<HV4G9>1.+=RS21I.W)16^L=LW"P)G<0TL`K7&BS$Y@[HHR*Z/P`%
M0*`_1I`M).7JCY*T)N#Z2_94:^%:4I^+5:_DL]*C/Y:\8YR;F'^3\>L1DG+H
M$_S%;S1,PO%UDRT&38IE`>ZL<*;R`%1`H:^:/YM_RS;OOE_4[C]"6QKU&B+B
MWI@FK,LVN$1C+FRYI[?=94[<QVF\JBG28@2D</(G@H^6B%T0[LI)*%FFPI"!
M3(.6RR3A/:;:HF=`P`=,P@%!`?+7S;NND^L]HN8QIV&X6]Y"HY@:4XAQCBZY
MKC=[1?VTH1KT)&/'4"Z59E?UT!(M'RC&2*5!PP,DF#90H))-E4MH)U&A/@)4
M?KU[SM_5W<JVW*A=7=G>R%*I3,3HDT=,HDGY!>M_<-LF)1,X`&)XKSE+[N=2
M5>OTF$D)G#Q\J%$CB"A'!U0'?3H8!*I7[=>9N'7?<6YW.^G"RO?NUS7E.1T2
M]3NWVNBVVK:X6M*F9T]7N8XY#Q/))>]2N>86!!O%2[HQS@DDBBV656,:NTA2
MID#<<U1Z!KCRCT_UMOEWA8[C<W$I,(BE(L^0P"]FE7VJSIF5:XH`1&'J&2?=
MQ/XOW)'3T?DK(<6:,3C:KV[;SPASR!GPA_!EI!&A19F:?B23,%>H]=?17\J'
MY7]_VG?*/<GK^U%"-('[M;S!]T$LTY0PT^1"X@Z^Z]MKC;Y;#MDHRISEZY1+
MCR?C_@I+GH/W#1ZBP5]%(*-'";)XN@99NV=&3$$7*B)1(98B1Q`1*`@(TI77
MTWC2E3!(DY)?X<!\%P3*3R]MAHCDH*.17L]9PY?R23GD7S:NB\8F*D)-];=I
M1MM.(:U8`L@HL4HMHPDF;NN",CE1,=0YZ@6H4'P;'CFK)B?%/%X@\/N3'&63
MMRW;AY<267,,VU%C%1MB7-:JB<HP:HI'28-F,\5\)4V;(!*!$S)&^$OCI@2=
MTC($,GR98@+ZNG'MVV_C6\$\?WS*Q@L[9O)S&FF&]OR)U$E"R*D815N=X0B2
M9R"0#EZG`:]-5)_@IB0,3BH&LT>Q??W)6_'&2^0?,.X+_O!9JA'-WA;548MX
MR,:"J+6-CTTY$X),VXKF$I35'XAJ(ZD"2LRBE\XS>V5R>XEN+=@<4<Z+D/BB
M*G6D@^Q?<MJ.)F!5C_4%/)LXHQI0%XQQ()$`@J`<Q"T`=FAI<4:HI:^5?#/E
MER/N*\XZ`YJSF)L/76B#`F/+6M0Z;U&(7C6[*3BY&X!?5?-WZQ53FV)I4*I2
MHTJ(Q0)1`YJ.^P?\/F[Q)=4'D#%/+F][$R';"YG4#=41#+%>1[DR9DE#)G.^
M%-5%=-0P*%.!@-N'0TD:H#Q4WW&?&F<,5VG*P.=\X_SVF%9!%:%N9>WAMYXR
M8E2,1=F^+ZMRF]666,!BG+L`H!2@^.F`7]62F4@?I"CW]P[V>L?\Y<J6WE^-
MO8<6WDR@D[>NU^UA%I4MW,&-`@Q6*W=LRH.(E(ZI0..X1`X?0&D02<,D`AFD
M[HO'/VU^47%LEK6[C#GA>3G&,%)-W;G'5W6TM/PQV8J@>0912JTB5Y'%=E*`
M!N44!/Z-+3+ADKUP\U)QFK`>)>15AO<<YJL6"R!;4@@F5VUF8XJIT7:25$W\
M8Y`2.6;Q!8>XF8I]H&`*@-*:;'P4N!DH?[:]H7,/&*\Y.Z>`7,"[,,6[,*`^
ME<9Y*CWE_P!HR[Q`^Y!)VB@O&E;M$4@[1")@0=H`(FT-)/5'XIQ1K)]XR7;'
MAW6<>)%L%5*+=2Z&&);I?OA34#89RW8#>@IH.2%$3%':(`:G31ZC@CT9NFE7
MG['UY\CKM0O/F5S/R7F:69G0+'(0+-Q:D;$,D5BN/ET6R.N_;(MC*$ZB8ASB
M'[6C2>"6J+<5(WE[BQFN4Q;C##?&OD;*<=;1L2WB6O(/HVW_`)Q=,M&-6R39
MB9E,>H;-XQTB!3"904C[A-X!HTR3$XXOBHU,6>QUDK`F1#Y@PSS1NRV,H.0D
M_F%SO[=7EU)?YSN-*$EBN),QG:;TYA$U1*(5Z4Z:-)3$XNIX<4P%\VOCVVH'
M)5XM[_OB-8G0G[P:11X1";==]4Q'2<6==T=KM0,0M.X:HEKYZL.`LI$$N$Q+
MF/PZY+<HG]T6U;G+1YB;"MUP[.)DL?PMI'>23M$J*!91-W/"_(4S6072,?ME
M2`0`U-VI(D<U8E$1T\5&K8O^'L=8JN6$OK%/+F];`OVW'*3Z`NN"B5VSZ-<H
ME$I!33&0,EVQ(82B10#E$HC4-#%F.:>J'#[5)5_=GYV_RF_(W]^1+\X_/-_\
MQ?Y:K?.OD'<_V?\`[7[?S#M]/5;-M>NW4Z9.R>N#9*24Y3%[H$H4QC5Z&ZB/
MZ!\]$0""(B(/FL"3"6J+ZEJCQ<<81$\5&G.(B)CJQ[%0YA'Q$3G1,8PB/TCK
M\ZKMFU2F9&WMY5#F33B2?BR\JE<W%0/.<HGD3B@$1$CT^41?_P!;&@'WM]9_
MA>TG#[K:_P#%'^%;^_5_\U3_`'%&"'B/.'B1_P#CXW^A#3_"=I_^2U_XH_PI
M&M7/]:I_N**G$QB(F41B8E,Q3"(&3CF1#E,(]!`Q4`ZA](:TCMEE2:I1M[>)
M'&-.(/V+.58R+5:TY89$DK:M!W=P=QS=0"IZ[NE>E?"@5\M>?0JBH"/4X\0R
M\:8IC^7D5]FMU";]GW,\GA^-MPT3;A+@D+LF$8&-*=Z@@5!^X$H)&4:F.5RX
M2#>`B*8=`U$G=7$!DNL>=VI'L%)`A$GZC)HH^22KVTGAT"&=)I[A$W;(L)@"
MM1IJ@[8J3@62=99R%)XWMYE-1%GR]ZN74RPBSQD.!?4-T7AQ*=\<3$.`HH`%
M3:4BV"<0#FE+;JBNW07,F=$RR*:ID5*=Q(3E`PIGITW$K0=4%*]M"%XKKH-D
M5'#E9)N@D43JKKJ$112(`5$ZBJABD(4`#J(B`:1+!TP'+!!NX0=(IN&JZ+EN
MJ7<DNW5(N@J4?`R:J8F3.4?I`=`+AT$,67`Y5O57'5AS]YIQ7SDL$S.\79"[
M;L]Z0"4@""SDQ4Q'N'`-H?$->FIF[8)Q`*^##%XSU_X\A+PN&+1AG4YZAXTC
MT1.8$(LYP]`"ACB83*BE^(0&@CIP*)``I4]4I0T(0T(0T(0T(0T(0T(0T(0T
M(0T(0T(6!(4#&H`>.L_:@?41BJ)(P&2*)"#XE`=7I`R2<E#MD_JAIL$CC@4-
MA/ZH:%.F*`$(`4`H4'J.@`#)6C``!T`*:0B!B,TD!\.GCY?;Y??H)8)A1TWI
M<$_E?E(E%VG'-)=CB&*72:KR0JGMIA<3\I@/,RBZ(&J9BDN';(2I@43#<`%Z
MZSQ*T`8XI?>-60+\OVWKP7OIPUD'-OW:]A&$S'M`;,Y-LS,NFX5:)D23(HFF
MX2VE-3PT.>"4@.*Y1[E3*DSR&M?'<"FPC;?9IN92](P2)O'C:WDCB5H]=O4P
M51:+RY3D.@D10#E)7>`#H)+XY)@!DIF;<OJXZ0@8.W(].=OR]7Z,5:D.J=4J
M0+JFV*R#_L?QRMFU0,/TZ9/!(#BN/LK(MZQ>;!PY>$VC=*[^Q&UVJ2*#%LQ&
M"E!.Z%[$$(S23(JR*DF0$CJ_QA$1KY:`?!!&"Y?EY=URE@('%L"U(1QDZ5;P
M19$%U2/DVW=2,[.V1;FW@0$3#N,<`"E>ND\CGDF`!B,UY8GNV][#S&;CW.3#
M:ZX"-LV+?0THFS2:2$.=%)NDJU=E;))I*MSANHH<1,)A\:CH!(.&2)!_-?#S
M2N<Y8&T,9,R+O7E\7"Q,[8L=ZCIS$M7!15;%2+4P@LX*0!$0I2N@G'%$1X9H
MJ%^9=L;,>'L>R7R1*U;U8KMS6?&-3'<VO%QR:)$EW;X$A6,[*!P[H;Q1*/X1
MIH=L!F@@%.HOV_HBQV+0[GOOYB6=D86_`,`*I)S,@H8`3002$![:)1$!.H?:
M0H#41#5$X89J8Q?/)-W?7SF>7S+9>/(^6@XEN+(]V7HWAV_S-2&B0$P-H.15
M>)*%0</%$!()@-O`QOAZ4'4N>*L@`+K.3>3;OQ?8SZ;M,6+)4B15"S$EL7[;
ME9<K=.,8,OXGJG@[@4$#D$-G@-=-Y*0`,UI\;SG(B]7&/;MDEX"'L9TP;A<L
M,X9JIS\D(M1%223'L@FT!=Q0Q"%$H;!H(5T8G)$@!R6JY2YEO?&$9$(66*+&
M0E))@U:*+-RR$C-KNE`[J,,P,1<AT6WX5Q4*42B<NSI4=#DG%,`,N/F<V9KC
M,H8^M1)",?25T1!W<G8#1N116$0703%E)7!*`056)]V\RQ"*@0H4H&I<ID!D
MH>`\A9,O/(.4X^YI6,G;+M9ZC&0\M'-"-VWSD#@+UDQ<I)$!ZV:I*`43*")@
M$!U42>2F0#89I9;ROM6+E6%H6NT0G+TEDS+I,EESDCX6.3$05EYU5`P*MFH4
M$I2A\9C!X4T$XX9I`8.4B&*+]R9?V9+TB7$_&/<=X^;)1;EQ"M=S6;N=P)5E
MT"/ETB*"A'%WIAL-\0%J/70"?BG(`)W9`$"]1$1J(]:>8^`?5]&K&2@H^FDL
MF_$/VCH&29S6-"2&A"&A"&A"&A"^=T*H-UO3F*1<4S`@8X5(540^`3_N@/C]
M6E++!,9IB.(<>Y=@K9NVQ?RL6U9"Z+GG'USW\\6*LH]CI%XX*`Q"53BY<*1Z
M@)DWB0$Q&H=0"F6*U)'%/)MFV(^Q+6:6_;34J;2*8J]A$_PJ/'W:,<RS@P>*
MSQU\1QK^(PZHQ8*-3GDFU\><;9#@;@O6[KU9HPDA=%ROY-^F8Q7,A)-4EE2Q
M39,Q_P#T$8U:JB40(8>X(`)@`0TE>"WF2[&N`,SV1EJ,A'MTLK>@Y&-5AF`D
M%VVD'0)@R>D3.HF4$1$IMY@-4`#PT8CS0&(6ZPYBB4A+GO#*][BF:^[Z>"IZ
M!$XJ-K;ABB'IHA`P@`BIMKW!IYTTQ%\5,I#(9)"I)_.WERKF;B9VV]NR"Q!'
M&@$VD88BABS,D@"Y5B`JHFD91('8%4H-2`4?'2/+-6!@G!8FQD_B[KO++5XI
M)IWU?AT&YV*2G=;V]`L2D39QC<Q@`045!$BBO[]?'QTP,7\%$B,@N%NJP[Z/
MF>[LNH6TA<'Y5M>,C\:0KAT*1)"44114E%Q$@"9NH54IP*(>6D0QP5!FQ7=6
M!9,Q+W<IF2_XP(:['4(V@HBW"K"X0MIDF0Q'YRK&^)5S*FV&.'@38%!'2#G%
M22!@N`O*VLLJ<AT+MMVWV,C;J=B(Q$5.2JXD96[).1=!*/$4BE4[CLZ9DPVB
M``;:`5TSXIAC%CDM#QMQGE.U;MO:Y;[`&;R=G'J[U\Y`B[^XF(;?0H$$3&](
MS:*E[A1*;<>NT0`-',)G+FNWS9C"XLKW_C*,.W3#',`\5N:Y5S&^-68;JF(Q
M8E*(4$ARID$WU#HQ^"G!G.:<\@F":2:14RHD(4$TTB?A23+\)"$\@*4OAK08
M!0<TV-[CBY;LSF]R!=<8FK;N/88C;&4>=7<$A-ND#*2$BL7]DQ72)`+]`&UG
MGDM'9DF3#%^5(FR\PY#-%%<9LR0H]C6#1!;<>#@%C=M$C$YA+M7(@81$*AX>
M.C!/+`)<././)S'-A14-.D:QR@,T#+0[<I5S$?*+J.'LC(O!`%7,@\%3:>H"
M`%*``(Z&?X)&7R3>"V9R$1?YY.R@V[20O!5T:'NM18%)-W%`V].VAHA`?X::
M8[0.)A,42B(B`:3)N/%+1Q;QM=F.+"8QMR-D8@YD5%%XD#>J?N9)TJ#AS*2K
MTX`H9R!]Q"$J8`(/CJXYNID0S!.>U:S0T(63?B'[1T#),YK&A)#0A#0A#0A#
M0A%-MVCNIMH.ZOA3SKH+-CDGY(%I7X?':7P\=O[/Z-+!^:,?@@?;^W3Q\_IZ
MZ>",7YHH]OK7;^`U:T_!4-U?W:TU/H3Q10[/EM\0K]O6F@Z>+(#\%R%]?G;\
MM2'\NOEGYJV)?+?G-/EGXA[O<KTW[:4TI._^E.+<4TOA3^9_D^0_S)\G[WYN
MD?G7;V_._G_<#U7S']OT?:IV:]-M*:09QX*ILR?.7;M#93;0-M/"GE36@Y+)
M8#;Y4_'_`-^@_?2NE@^&:>+<D/@^#P\]G]--'IX(Q13=JGQ[:5#QI2OEJ?1R
M3]7-`>UM+7;LW%VU\-]?A_375#3P2Q1C;*?%2GQ>/V#N^ZM=,-P1YK)=FT-E
M-E`VT_#MITI]5-`;@C'BB$[5?@VUZUI]_P"G2]*,4![51W;:^==&"2-\.\?#
MN4"O];;Y5^K1Z7PS5%^*P;MU#=MKNZ5I7=3_`*M(Z7QS2Q^"-\.XU*;OAW?3
32GPU_1IC2^&:"_%&TTD-"%__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
